Last reviewed · How we verify
MNV-201
At a glance
| Generic name | MNV-201 |
|---|---|
| Also known as | CD34+ cells enriched with allogeneic placenta derived mitochondria |
| Sponsor | Minovia Therapeutics Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the MNV-201 in Patients With Low Risk MDS (PHASE1)
- Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria in Patients With a Diagnosis of Pearson Syndrome (PS) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MNV-201 CI brief — competitive landscape report
- MNV-201 updates RSS · CI watch RSS
- Minovia Therapeutics Ltd. portfolio CI